Establishment of Baseline Urinary Antimicrobial Peptide Levels by Age: A Prospective Observational Study.
Caterino. Jeffrey M JM; Stephens. Julie A JA; Wexler. Randell R; Camargo. Carlos A CA; Hunold. Katherine M KM; Wei. Lai L; Hains. David D; Southerland. Lauren T LT; Bischof. Jason J JJ; Schwaderer. Andrew A
Key Findings
- Urinary LL‑37 levels are similar in adults younger and older than 65
- Older adults have significantly lower urinary hBD‑2 compared to younger adults
- Urine leukocyte esterase, hematuria, and contaminated cultures affect other peptide levels
Practical Outcomes
- For biohackers, the data imply that boosting LL‑37 specifically for age‑related urinary health isn’t supported by this study. However, the lower hBD‑2 in older adults could motivate exploring ways to raise hBD‑2 (e.g., diet, supplements) to improve urinary immunity. Monitoring urinary peptide levels might help gauge infection risk, but more research is needed before changing protocols.
Summary
The study measured levels of several antimicrobial peptides in urine, including LL‑37, and found that age doesn’t change LL‑37 levels, while older people have lower levels of another peptide (hBD‑2). This suggests that simply aging isn’t a reason to expect more or less LL‑37 in urine, and that lower hBD‑2 might be part of why older adults get more UTIs.
Abstract
Antimicrobial peptides (AMPs) are key effectors of urinary tract innate immunity. Identifying differences in urinary AMP levels between younger and older adults is important in understanding older adults' susceptibility and response to urinary tract infections (UTI) and AMP use as diagnostic biomarkers. We hypothesized that uninfected older adults have higher urinary human neutrophil peptides 1-3 (HNP 1-3), human alpha-defensin-5 (HD-5), and human beta-defensin-2 (hBD-2), but lower urinary cathelicidin (LL-37) than younger adults. We conducted a cross-sectional study of patients aged ≥18 years completing a family medicine clinic nonacute visit. Enzyme-linked immunosorbent assays were performed for AMPs. We identified associations between age and AMPs using unadjusted and multivariable linear regression models. Of the 308 subjects, 144 (46.8%) were ≥65 years of age. Comparing age ≥65 versus < 65 years, there were no significant differences in HNP 1-3 (p = .371), HD5 (p = .834), or LL-37 (p = .348) levels. Values for hBD-2 were lower in older adults versus younger (p < .001). In multivariable analyses, older males and females had significantly lower hBD-2 levels (p < .001 and p = .004). Models also showed urine leukocyte esterase was associated with increased levels of HNP 1-3 and HD5; hematuria with increased hBD-2; and urine cultures with contamination with increased HNP 1-3 and hBD-2. Baseline urinary HNP 1-3, HD-5, and LL-37 did not vary with age. Older adults had lower baseline hBD-2. This finding has implications for the potential use of urinary AMPs as diagnostic markers and will facilitate further investigation into the role of innate immunity in UTI susceptibility in older adults.
Study Information
pubmed
2024
2024-06-01T00:00:00.000Z
10.1093/gerona/glad223
2